ty. Results: Comparison between the studied groups regarding the primary outcomes revealed no statistically significant differences. Primary patency rate was 65.7% and 68.0% (P ¼ .58) at 6 months and 53.8% and 56.4% (P ¼ .57) at 12 months in the sAVG and eAVG groups, respectively. Primary assisted patency rate was 70.8% and 69.7% (P ¼ .8) in patients with sAVG and eAVG, whereas the reported rates at 12 months were 59.3% and 61.0% (P ¼ .71), respectively. Secondary patency rate was 78.4% and 73.9% (P ¼ .25) at 6 months and 67.8% and 69.7% (P ¼ .65) at 12 months in the sAVG and eAVG groups, respectively. As expected, patients in the eAVG group experienced significantly earlier cannulation when compared with patients in the sAVG group (median, 3.0 days; range, 1.0-9.0 days vs 19.0 days; range, 15.0-22.0 days; P < .001). Conclusions: Patients in the eAVG group have comparable outcomes to those in the sAVG group at 12 months with the added advantage of earlier time to first cannulation. (J Vasc Surg 2022;75:1047-53.) Keywords: Early cannulation arteriovenous graft; Hemodialysis access; Standard arteriovenous graft